Prevention of MDR development in leukemia cells by micelle-forming polymeric surfactant

Journal of Controlled Release

Volumn 131, Issue 3, 2008, Pages 220-227

  Sharma, Amit K ^a,b   Zhang, Li ^a,f   Li, Shu ^a   Kelly, David L ^c   Alakhov, Valery Yu ^d   Batrakova, Elena V ^a   Kabanov, Alexander V ^a,b,c,d,e  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b NEBRASKA MEDICAL CENTER   (United States)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^d Supratek Pharma Inc   (Canada)

^e MOSCOW STATE UNIVERSITY   (Russian Federation)

^f SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Doxorubicin; Multidrug resistance; P glycoprotein; Pluronic; Poloxamer

Indexed keywords

ABS RESINS; ASSAYS; BIOCHEMISTRY; BLOCK COPOLYMERS; CELL DEATH; COLLOIDS; COPOLYMERIZATION; CYTOLOGY; GENE EXPRESSION; GLYCOPROTEINS; MICELLES; OLIGONUCLEOTIDES; PLASTIC PRODUCTS; POLYMERS; SURFACE ACTIVE AGENTS; TUMORS;

DOXORUBICIN; MULTIDRUG RESISTANCE; P-GLYCOPROTEIN; PLURONIC; POLOXAMER;

CELLS;

COPOLYMER; DOXORUBICIN; GLYCOPROTEIN P; PLURONIC P 85; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG FORMULATION; FEMALE; GENE; IC 50; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA CELL; LEUKEMIA P 388; MDR1 GENE; MICELLE; MICROARRAY ANALYSIS; MOUSE; MULTIDRUG RESISTANCE; NANOPHARMACEUTICS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUORESCENT DYES; GENES, MDR; INHIBITORY CONCENTRATION 50; LEUKEMIA P388; MICE; MICE, INBRED STRAINS; MICELLES; P-GLYCOPROTEIN; POLOXALENE; RHODAMINE 123; SURFACE-ACTIVE AGENTS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 54249111320     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2008.07.031     Document Type: Article

References (54)

1. Torchilin V.P. Targeted pharmaceutical nanocarriers for cancer therapy and imaging. AAPS J. 9 2 (2007) E128-147
2. Duncan R. Polymer conjugates for drug targeting. From inspired to inspiration!. J. Drug Target. 14 6 (2006) 333-335
3. Koziara J.M., Whisman T.R., Tseng M.T., and Mumper R.J. In-vivo efficacy of novel paclitaxel nanoparticles in paclitaxel-resistant human colorectal tumors. J. Control. Release 112 3 (2006) 312-319
4. Lamprecht A., and Benoit J.P. Etoposide nanocarriers suppress glioma cell growth by intracellular drug delivery and simultaneous P-glycoprotein inhibition. J. Control. Release 112 2 (2006) 208-213
5. Werle M., and Hoffer M. Glutathione and thiolated chitosan inhibit multidrug resistance P-glycoprotein activity in excised small intestine. J. Control. Release 111 1-2 (2006) 41-46
6. Ho E.A., Soo P.L., Allen C., and Piquette-Miller M. Impact of intraperitoneal, sustained delivery of paclitaxel on the expression of P-glycoprotein in ovarian tumors. J. Control. Release 117 1 (2007) 20-27
7. Batrakova E.V., and Kabanov A.V. Pluronic block copolymers: evolution of drug delivery concept from inert nanocarriers to biological response modifiers. J. Control. Release (Apr 24 2008) [Electronic publication ahead of print]
8. Danson S., Ferry D., Alakhov V., Margison J., Kerr D., Jowle D., Brampton M., Halbert G., and Ranson M. Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP1049C) in patients with advanced cancer. Br. J. Cancer 90 11 (2004) 2085-2091
9. Matsumura Y., Hamaguchi T., Ura T., Muro K., Yamada Y., Shimada Y., Shirao K., Okusaka T., Ueno H., Ikeda M., and Watanabe N. Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin. Br. J. Cancer 91 10 (2004) 1775-1781
10. Mizumura Y., Matsumura Y., Yokoyama M., Okano T., Kawaguchi T., Moriyasu F., and Kakizoe T. Incorporation of the anticancer agent KRN5500 into polymeric micelles diminishes the pulmonary toxicity. Jpn. J. Cancer Res. 93 11 (2002) 1237-1243
11. Armstrong A., Brewer J., Newman C., Alakhov V., Pietrzynski G., Campbell S., Corrie P., Ranson M., and JW V. SP1049C as first-line therapy in advanced (inoperable or metastatic) adenocarcinoma of the oesophagus: a phase II window study. J. Clin. Oncol. 24(18S) (2006) 4080 ASCO Annual Meeting Proceedings Part I
12. Kabanov A., and Alakhov V. Pluronic block copolymers in drug delivery: from micellar nanocontainers to biological response modifiers. Crit. Rev. Ther. Drug Carr. Syst. 19 1 (2002) 1-72
13. Alakhov V., Moskaleva E., Batrakova E.V., and Kabanov A.V. Hypersensitization of multidrug resistant human ovarian carcinoma cells by pluronic P85 block copolymer. Bioconjug. Chem. 7 2 (1996) 209-216
14. Kabanov A.V., Batrakova E.V., and Alakhov V.Y. Pluronic block copolymers for overcoming drug resistance in cancer. Adv. Drug Deliv. Rev. 54 5 (2002) 759-779
15. Venne A., Li S., Mandeville R., Kabanov A., and Alakhov V. Hypersensitizing effect of pluronic L61 on cytotoxic activity, transport, and subcellular distribution of doxorubicin in multiple drug-resistant cells. Cancer Res. 56 16 (1996) 3626-3629
16. Gottesman M.M., Fojo T., and Bates S.E. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat. Rev. Cancer 2 1 (2002) 48-58
17. Robey R.W., Polgar O., Deeken J., To K.W., and Bates S.E. ABCG2: determining its relevance in clinical drug resistance. Cancer Metastasis Rev. 26 1 (2007) 39-57
18. Szakacs G., Paterson J.K., Ludwig J.A., Booth-Genthe C., and Gottesman M.M. Targeting multidrug resistance in cancer. Nat. Rev. Drug Discov. 5 3 (2006) 219-234
19. Fojo A.T., Ueda K., Slamon D.J., Poplack D.G., Gottesman M.M., and Pastan I. Expression of a multidrug-resistance gene in human tumors and tissues. Proc. Natl. Acad. Sci. U. S. A. 84 1 (1987) 265-269
20. Kohno K., Sato S., Takano H., Matsuo K., and Kuwano M. The direct activation of human multidrug resistance gene (MDR1) by anticancer agents. Biochem. Biophys. Res. Commun. 165 3 (1989) 1415-1421
21. Fox E., and Bates S.E. Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor. Expert Rev. Anticancer Ther. 7 4 (2007) 447-459
22. Thomas H., and Coley H.M. Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. Cancer Control 10 2 (2003) 159-165
23. Polgar O., and Bates S.E. ABC transporters in the balance: is there a role in multidrug resistance?. Biochem. Soc. Trans. 33 Pt 1 (2005) 241-245
24. Wuchter C., Leonid K., Ruppert V., Schrappe M., Buchner T., Schoch C., Haferlach T., Harbott J., Ratei R., Dorken B., and Ludwig W.D. Clinical significance of P-glycoprotein expression and function for response to induction chemotherapy, relapse rate and overall survival in acute leukemia. Haematologica 85 7 (2000) 711-721
25. Tothova E., Elbertova A., Fricova M., Kafkova A., Hlebaskova M., Svorcova E., Stecova N., Guman T., and Raffac S. P-glycoprotein expression in adult acute myeloid leukemia: correlation with induction treatment outcome. Neoplasma 48 5 (2001) 393-397
26. Gyemant N., Tanaka M., Molnar P., Deli J., Mandoky L., and Molnar J. Reversal of multidrug resistance of cancer cells in vitro: modification of drug resistance by selected carotenoids. Anticancer Res. 26 1A (2006) 367-374
27. Isayeva T., Ren C., and Ponnazhagan S. Recombinant adeno-associated virus 2-mediated antiangiogenic prevention in a mouse model of intraperitoneal ovarian cancer. Clin. Cancer Res. 11 3 (2005) 1342-1347
28. Ferrari M., Fornasiero M.C., and Isetta A.M. MTT colorimetric assay for testing macrophage cytotoxic activity in vitro. J. Immunol. Methods 131 2 (1990) 165-172
29. Batrakova E.V., Li S., Elmquist W.F., Miller D.W., Alakhov V.Y., and Kabanov A.V. Mechanism of sensitization of MDR cancer cells by pluronic block copolymers: selective energy depletion. Br. J. Cancer 85 12 (2001) 1987-1997
30. Miller D.W., Batrakova E.V., Waltner T.O., Alakhov V., and Kabanov A.V. Interactions of pluronic block copolymers with brain microvessel endothelial cells: evidence of two potential pathways for drug absorption. Bioconjug. Chem. 8 5 (1997) 649-657
31. Wang H.Y., Malek R.L., Kwitek A.E., Greene A.S., Luu T.V., Behbahani B., Frank B., Quackenbush J., and Lee N.H. Assessing unmodified 70-mer oligonucleotide probe performance on glass-slide microarrays. Genome Biol. 4 1 (2003) R5
32. Batrakova E.V., Kelly D.L., Li S., Li Y., Yang Z., Xiao L., Alakhova D.Y., Sherman S., Alakhov V.Y., and Kabanov A.V. Alteration of genomic responses to doxorubicin and prevention of MDR in breast cancer cells by a polymer excipient: pluronic P85. Mol. Pharmacol. 3 2 (2006) 113-123
33. Naito S., Koga H., Yokomizo A., Sakamoto N., Kotoh S., Nakashima M., Kiue A., and Kuwano M. Molecular analysis of mechanisms regulating drug sensitivity and the development of new chemotherapy strategies for genitourinary carcinomas. World J. Surg. 24 10 (2000) 1183-1186
34. van der Kolk D.M., de Vries E.G., van Putten W.J., Verdonck L.F., Ossenkoppele G.J., Verhoef G.E., and Vellenga E. P-glycoprotein and multidrug resistance protein activities in relation to treatment outcome in acute myeloid leukemia. Clin. Cancer Res. 6 8 (2000) 3205-3214
35. Fojo T., and Bates S. Strategies for reversing drug resistance. Oncogene 22 47 (2003) 7512-7523
36. Batrakova E.V., Dorodnych T.Y., Klinskii E.Y., Kliushnenkova E.N., Shemchukova O.B., Goncharova O.N., Arjakov S.A., Alakhov V.Y., and Kabanov A.V. Anthracycline antibiotics non-covalently incorporated into the block copolymer micelles: in vivo evaluation of anti-cancer activity. Br. J. Cancer 74 10 (1996) 1545-1552
37. Alakhov V., Klinski E., Li S., Pietrzynski G., Venne A., Batrakova E.V., Bronitch T., and Kabanov A. Block copolymer-based formulation of doxorubicin. From cell screen to clinical trials. Colloids Surf. B Biointerfaces 16 (1999) 113-134
38. Batrakova E., Lee S., Li S., Venne A., Alakhov V., and K. A. Fundamental relationships between the composition of pluronic block copolymers and their hypersensitization effect in MDR cancer cells. Pharm. Res. 16 9 (1999) 1373-1379
39. Lee C.H., Bradley G., and Ling V. Increased P-glycoprotein messenger RNA stability in rat liver tumors in vivo. J. Cell. Physiol. 177 1 (1998) 1-12
40. Muller C., Goubin F., Ferrandis E., Cornil-Scharwtz I., Bailly J.D., Bordier C., Benard J., Sikic B.I., and Laurent G. Evidence for transcriptional control of human mdr1 gene expression by verapamil in multidrug-resistant leukemic cells. Mol. Pharmacol. 47 1 (1995) 51-56
41. Baker E.K., Johnstone R.W., Zalcberg J.R., and El-Osta A. Epigenetic changes to the MDR1 locus in response to chemotherapeutic drugs. Oncogene 24 54 (2005) 8061-8075
42. Chaudhary P.M., and Roninson I.B. Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell 66 1 (1991) 85-94
43. Bailly J.D., Muller C., Jaffrezou J.P., Demur C., Gassar G., Bordier C., and Laurent G. Lack of correlation between expression and function of P-glycoprotein in acute myeloid leukemia cell lines. Leukemia 9 5 (1995) 799-807
44. Fichtner I., Becker M., Lemm M., and Winterfeld G. Development of a mitoxantrone-resistant P 388 in vivo: approaches to overcome resistance. Oncology 47 6 (1990) 508-515
45. Fichtner I., Stein U., Hoffmann J., Winterfeld G., Pfeil D., and Hentschel M. Characterization of four drug-resistant P388 sublines: resistance/sensitivity in vivo, resistance- and proliferation-markers, immunogenicity. Anticancer Res. 14 5A (1994) 1995-2003
46. Nielsen D., Eriksen J., Maare C., Litman T., Kjaersgaard E., Plesner T., Friche E., and Skovsgaard T. Characterisation of non-P-glycoprotein multidrug-resistant Ehrlich ascites tumour cells selected for resistance to mitoxantrone. Biochem. Pharmacol. 60 3 (2000) 363-370
47. Nielsen D., Maare C., Eriksen J., Litman T., Friche E., and Skovsgaard T. Characterisation of multidrug-resistant Ehrlich ascites tumour cells selected in vivo for resistance to etoposide. Biochem. Pharmacol. 60 3 (2000) 353-361
48. Nielsen D., Eriksen J., Maare C., Jakobsen A.H., and Skovsgaard T. P-glycoprotein expression in Ehrlich ascites tumour cells after in vitro and in vivo selection with daunorubicin. Br. J. Cancer 78 9 (1998) 1175-1180
49. Batrakova E.V., Li S., Li Y., Alakhov V.Y., Elmquist W.F., and Kabanov A.V. Distribution kinetics of a micelle-forming block copolymer pluronic P85. J. Control. Release 100 3 (2004) 389-397
50. Nielsen D., Maare C., and Skovsgaard T. Cellular resistance to anthracyclines. Gen. Pharmacol. 27 2 (1996) 251-255
51. Kudoh K., Ramanna M., Ravatn R., Elkahloun A.G., Bittner M.L., Meltzer P.S., Trent J.M., Dalton W.S., and Chin K.V. Monitoring the expression profiles of doxorubicin-induced and doxorubicin-resistant cancer cells by cDNA microarray. Cancer Res. 60 15 (2000) 4161-4166
52. Sinha B.K., Mimnaugh E.G., Rajagopalan S., and Myers C.E. Adriamycin activation and oxygen free radical formation in human breast tumor cells: protective role of glutathione peroxidase in adriamycin resistance. Cancer Res. 49 14 (1989) 3844-3848
53. Licht T., Fiebig H.H., Bross K.J., Herrmann F., Berger D.P., Shoemaker R., and Mertelsmann R. Induction of multiple-drug resistance during anti-neoplastic chemotherapy in vitro. Int. J. Cancer 49 4 (1991) 630-637
54. Cocker H.A., Tiffin N., Pritchard-Jones K., Pinkerton C.R., and Kelland L.R. In vitro prevention of the emergence of multidrug resistance in a pediatric rhabdomyosarcoma cell line. Clin. Cancer Res. 7 10 (2001) 3193-3198